Evidence map›Paper›PMID 40162242›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Prevalence of deleterious cardiomyopathy variants in early-onset atrial fibrillation.

Quim Bech Vilaseca, Oliver Bundgaard Vad, Christian Paludan-Müller, Laura Andreasen, Morten Salling Olesen, Jesper Hastrup Svendsen, Pia Rengtved Lundegaard

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Quim Bech VilasecaORCID 0009-0003-8460-8696
Oliver Bundgaard VadORCID 0000-0001-8416-0543
Christian Paludan-MüllerORCID 0000-0002-7724-544X
Morten Salling OlesenORCID 0000-0001-9477-5322
Jesper Hastrup SvendsenORCID 0000-0001-8466-8515
Pia Rengtved LundegaardORCID 0000-0002-8284-1844

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Atrial fibrillation (AF) is a common cardiac arrhythmia associated with an increased risk of stroke, heart failure, and death. Recent studies suggests that individuals with early onset of AF could be at increased risk of developing heart failure and dilated cardiomyopathy. This study aimed to identifying genetic variants in a broad panel of cardiomyopathy genes among early-onset AF individuals. Methods: We conducted targeted genetic sequencing of 29 cardiomyopathy-associated genes in 478 individuals with AF onset below 45 years of age from a Danish cohort. Additionally, we analyzed whole exome sequencing data in 374,289 individuals from the UK Biobank, including 29,108 individuals with AF. The cohort was stratified by age at AF diagnosis, and individuals with pre-existing cardiomyopathy were excluded. We focused on rare, truncating variants predicted to lead to loss of function, and potentially deleterious missense variants in the UK Biobank. Results: In the Danish cohort, 42 (8.8%) individuals with early-onset AF had truncating genetic variants in known cardiomyopathy genes. The UK Biobank analysis showed an inverse dose-response-like relationship between age of AF onset and prevalence of truncating variants, ranging from 3.8% in the AF onset <45 years group to 1.4% in the group without AF diagnosis. The prevalence of rare missense variants showed a similar pattern. Conclusions: We identified a high prevalence of deleterious variants in cardiomyopathy-associated genes among individuals with early-onset AF. This supports recent guideline suggestions and indicates that genetic testing and surveillance for cardiomyopathy could be relevant in selected individuals with an early AF diagnosis.

Identifiers

PMID40162242
PMCPMC11952602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.